包装 | 价格(元) |
10mM (in 1mL DMSO) | 电议 |
100mg | 电议 |
Cell lines | VCaP or Hep-G2 cell lines |
Preparation method | The solubility of this compound in DMSO is >21.5 mg/ml. General tips for obtaining a higher concentration: Please warm the tube at 37℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months. |
Reacting condition | 10-11 -10-4 M |
Applications | Bicalutamide was found to be able to inhibit the growth in prostate cancer cells (VCaP cells) with overexpressed androgen receptor through directly binding to AR then mediating androgen-mediated gene transcription. Moreover, bicalutamide could impair the DNA binding and nuclear localization in prostate cancer cells. In HepG2 cells, bicalutamide could also significantly inhibit R1881-induced VP16-AR–mediated transcription with an IC50 value of 0.2 μM. |
Animal models | Male immunodeficient mice harboring LNCaP/AR-luc xenograft tumors |
Dosage form | 10 mg/kg/day, oral |
Application | In a clinically valid murine xenograft model of human CRPC, bicalutamide showed greater efficacy than MDV3100. Maximal therapeutic response in this model was achieved at 30 mg/kg/d of bicalutamide, whereas the same response required 100 mg/kg/d of MDV3100 and higher steady-state plasma concentrations. |
Other notes | Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
产品描述 | Bicalutamide is an active non-steroidal androgen receptor antagonist with IC50 value of 160 nM.[1] |